Endocrine Abstracts

The UKPDS trial confirmed that improving glycaemic control (median 0.9 % HbA1c difference over median 10 years), with sulphonylurea or insulin therapy, could reduce significantly the risk of microvascular complications (25%, p=0.0099) and was associated with a 16% trend (p=0.052) to a reduced risk of coronary heart disease (CHD). In overweight UKPDS patients allocated metformin as first line therapy the 0.6% median HbA1c difference obtained was associated...

Background: The safety of GH replacement in patients with craniopharyngioma has not been clearly elucidated.Aim: To assess whether GH replacement increases the risk of craniopharyngioma recurrence.Patients and Methods: The records of the patients with craniopharyngioma followed-up at the Departments of Endocrinology and Paediatrics between 1/1964-6/2004 were reviewed. The recurrence risks of GH-treated and non-GH-treated patients w...